Searched for
LENALIDOMIDE SALES DECLINE
Natco Pharma Q1 profit falls 57 pc to Rs 206.5 crNatco Pharma has reported a stark profit decline in the first quarter, largely driven by reduced sales of its leading cancer drug, lenalido...- US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipelineIndian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...
- Dr Reddy’s aims to resume semaglutide supply by November after API fixDr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and pla...
- Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concernsDr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue ...
- Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh inDr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...
- Dr Reddy's Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announcedDr Reddy's Laboratories Q4 Results: Dr. Reddy's Laboratories reported a consolidated net profit at Rs 221 crore in the March-ended quarter ...
- Biocon Q4 Results: Net profit down 57% at Rs 198.6 croreBiocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...
- Dr Reddy's Laboratories Q3 Results: Profit falls 14% YoY to Rs 1,210 crore, revenue up 4%Dr Reddy’s Laboratories reported a 14% YoY drop in Q3 net profit to Rs 1,210 crore, even as revenue rose 4% to Rs 8,727 crore. Lower margin...
- Dr Reddy’s Laboratories shares fall over 1% on Q2 results. Should you buy, sell or hold?Despite an uptick in profits, Dr Reddy's Laboratories experienced a decline in share value. Analysts continue to express optimism, keeping ...
- Can DRL’s new product launches offset the slowdown in Revlimid sales?Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US...
- Dr Reddy’s gets nod to make generic semaglutide for weight lossDr Reddy's Laboratories is set to launch generic semaglutide, a popular weight loss drug. An expert committee has approved their proposal. ...
- Dr Reddy's Laboratories Q2 Results: Profit rises 7% YoY to Rs 1,347 crore, revenue up 10%Dr Reddy's Laboratories Q2 Results: Generic drugmaker Dr Reddy's Labs reported 7% growth in its net profit at Rs 1,347 crore in the Septemb...
- Dr Reddy’s Q2 Preview: PAT may grow up to 11–18% YoY; revenue seen steady despite pricing pressure in USDr Reddy’s Laboratories is expected to post steady September-quarter earnings with 10–14% revenue growth led by India and Europe, though US...
- Biocon reports 95% YoY decline in net profit, operating revenue up 15%Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue grew 15% to Rs 3...
- Dr Reddy's net profit rises 2% to Rs 1,413 crore in Q3FY25Dr. Reddy's reported a 2% YoY profit increase to ₹1,413 crore in Q3 FY25, with revenue rising 16% to ₹8,359 crore. North America sales grew...
- Dr. Reddy's Q3 Preview: PAT may rise 10% YoY; US sales to be stableDr. Reddy's net profit for the third quarter is expected to grow 10% YoY, with revenues likely increasing 13% YoY, based on an average of f...
- Our key business segments well positioned for growth: CS Muralidharan, Sun PharmaHowever, our outlook on speciality products remains very positive and I expect our existing products will continue to grow. Even in the cur...
- Dr Reddy’s Q2 Results: Profit jumps 12% YoY to Rs 1,114 crore; revenue rises 9.4%Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) for the quarter rose about 40% on year to Rs 1,899 cro...
- Dr Reddy's gearing up to get substantial slice of Revlimid generic opportunity in USRevlimid is a top-selling cancer drug from Bristol Myers Squibb. Its generic form, called lenalidomide, is seen as Dr Reddy's most anticipa...
- Natco Pharma aims to diversify product portfolio in domestic marketInforming shareholders, the drug maker said its oncology segment suffered in the last financial year due to pricing controls from the gover...
Load More
